Dr Richard Welch is a Consultant Clinical Oncologist based at The Christie NHS Foundation Trust in Manchester.
Dr Welch studied Medicine at Birmingham University obtaining MBChB in 1983. He trained in Clinical Oncology receiving his Specialist Qualification in 1996.
Richard is the Lead clinician for female germ cell tumours at The Christie with a wide experience of chemotherapy. In addition he has over 10 years experience as Chair for Christie Drugs and Therapeutics committee for The Christie.
Dr Welch has had a significant input into oncology services in Bolton NHS, breast ovary, testicular cancer and acute oncology .
He has Published and Contributed to many accredited Publications including:
‘outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, pertioneum, and fallopian tube.’ (Jan 2011) : ‘The management of poor prognosis tertoma.’ (March 2010) : ‘SCOTROC 2B: feasibilty of carboplatin followed by doxetaxel-irinotecan as first-line therapy for ovarian cancer’ (Jan 2006) : ‘Stage- and CA125- related survival in patients with epithlial overian cancer treated at a cancer centre.’ (2006) and many more.
